B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SMYD2

MOLECULAR TARGET

SET and MYND domain containing 2

UniProt: Q9NRG4NCBI Gene: 569501 compounds

SMYD2 (SET and MYND domain containing 2) is targeted by 1 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SMYD2

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1s adenosylhomocysteine0.691

About SMYD2 as a Drug Target

SMYD2 (SET and MYND domain containing 2) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 1 compounds with documented SMYD2 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SMYD2 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.